#Israel #Rehovot #Evogene #Tel Aviv University #Ehud Gazit

Introduction

Evogene Ltd., a frontrunner in computational biology and chemistry, has announced an exciting collaboration with Professor Ehud Gazit from Tel Aviv University, known for his groundbreaking work in molecular self-assembly. This partnership aims to accelerate the discovery and optimization of novel small molecules that could potentially serve as drug candidates for various metabolic diseases, particularly those linked to the pathological aggregation of metabolites.

Understanding Metabolite Disorders

The accumulation of metabolites in the body, often resulting from dysfunctional metabolic pathways, triggers the formation of harmful aggregates. Conditions such as Tyrosinemia, Gout, and Maple Syrup Urine Disease (MSUD) exemplify how these aggregations can lead to significant health challenges. Recognizing the need for effective therapeutic strategies, this collaboration seeks to address these critical medical gaps.

The Collaboration Goals

The primary objective of this joint effort is to design innovative small molecules that can effectively inhibit the self-assembly processes of these pathogenic aggregates. By slowing down or preventing this process, the collaborators aim to develop groundbreaking therapies that could significantly impact the health of millions.

Leveraging Cutting-Edge Technologies

Evogene plans to utilize its advanced ChemPass AI platform to facilitate molecular design and enhance therapeutic efficacy. This proprietary technology combines state-of-the-art computational capabilities with generative models aimed at optimizing drug candidates. Meanwhile, Professor Gazit's extensive knowledge of molecular behavior will inform the development of these novel compounds, ensuring they specifically target pathological processes.

Insights from Professor Ehud Gazit

Professor Gazit expressed his enthusiasm about this collaboration, highlighting the unique intersection of their research. His team's investigations over the past decade have unveiled the mechanisms through which small metabolites can form amyloid-like structures. This collaboration presents a remarkable opportunity to merge fundamental scientific insights with innovative drug design strategies, leading to potent new therapies for patients suffering from metabolic aggregation diseases.

Comments from Dr. Gabi Tarcic

Dr. Gabi Tarcic from Evogene emphasized the significance of this partnership, recognizing it as a pivotal milestone in addressing complex medical issues through AI and computational chemistry. The synergetic approach of combining deep scientific understanding with advanced technology holds promising prospects for developing innovative therapeutic solutions.

Evogene’s Commitment to Innovation

Evogene Ltd. is dedicated to transforming life-science product development through big data and artificial intelligence. With a focus on enhancing success rates while reducing time and costs, Evogene has created three unique tech engines: MicroBoost AI, ChemPass AI, and GeneRator AI. Each engine specializes in different components such as microbes, small molecules, and genetic elements, contributing to a comprehensive approach towards drug development.

Strategic Partnerships

In addition to its collaboration with Tel Aviv University, Evogene continues to foster partnerships aimed at creating and advancing therapeutics across various sectors. Subsidiaries like Biomica and Lavie Bio, powered by MicroBoost AI, are examples of how Evogene is leading in microbiome-based treatment innovations, showcasing its commitment to impactful health solutions.

Conclusion

The collaboration between Evogene Ltd. and Professor Ehud Gazit promises to deliver breakthrough innovations in combating metabolic diseases linked to toxic metabolite accumulation. By harnessing advanced AI technologies and profound scientific insights, this partnership is poised to make significant strides in drug development, paving the way for improved health outcomes for countless patients in need.

For further updates and information about Evogene, please visit Evogene's official website.